Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7084454 | 0.84 | PTGS2 (0.59) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL7087905 | 0.84 | PTGS2 (0.46) | PTGS2CA1CA2PTGS1DRD1 | |
| SCHEMBL7085561 | 0.79 | PTGS2 (0.56) | PTGS2PTGS1HSD11B1RORC | |
| SCHEMBL17069270 | 0.77 | PTGS2 (0.47) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL7089387 | 0.75 | PTGS2 (0.48) | PTGS2PTGS1RORCKMT2A | |
| SCHEMBL7085155 | 0.75 | PTGS2 (0.48) | PTGS2PTGS1 | |
| SCHEMBL7090583 | 0.73 | PTGS2 (0.53) | PTGS2 | |
| SCHEMBL28301092 | 0.73 | PTGS2 (0.71) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL7087907 | 0.71 | PTGS2 (0.61) | PTGS2PTGS1DRD1 | |
| SCHEMBL17071839 | 0.70 | PTGS2 (0.47) | PTGS2CA1CA2CA9PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | FFAR1 217/4885FFAR4 142/4885PTGS2 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.